About Entera bio ltd.
Entera Bio Ltd. is a leading biopharmaceutical company that specializes in the development of innovative technologies for oral drug delivery of large molecules. The company has been at the forefront of clinical trials for three oral drugs based on a proven active compound, and its managers have over 50 years of experience in drug development.
Entera's technology is designed to overcome the challenges associated with traditional methods of drug delivery, which often require injections or infusions. By enabling oral administration, Entera's technology offers patients a more convenient and less invasive way to receive treatment.
One key advantage of Entera's technology is its ability to deliver large molecules such as proteins and peptides orally. These types of molecules are typically difficult to administer via traditional methods due to their size and complexity. However, Entera's proprietary platform allows these molecules to be encapsulated in enteric-coated capsules that protect them from degradation in the stomach and facilitate absorption in the small intestine.
Entera has conducted extensive preclinical studies on its technology, demonstrating its safety and efficacy in animal models. The company has also completed several successful clinical trials on human subjects, further validating the potential benefits of its approach.
In addition to developing its own pipeline of drugs, Entera also partners with other pharmaceutical companies to help them develop new products using its technology platform. This collaborative approach allows Entera to leverage its expertise while expanding its reach into new therapeutic areas.
Overall, Entera Bio Ltd.'s innovative approach to oral drug delivery represents a significant advancement in the field of biopharmaceuticals. With a strong track record of success and experienced leadership team at the helm, this company is poised for continued growth and success in the years ahead.